Prognosis
European Union in Talks With Gilead to Secure Covid Drug Supply
- EU seen clearing remdesivir for coronavirus use this week
- U.S. deal sent ‘shivers’ through EU, Danish official says
This article is for subscribers only.
The European Union is in talks with Gilead Sciences Inc. about reserving a “sufficient number of doses” of remdesivir for the bloc’s member states after the U.S forged a deal to snap up almost all the drugmaker’s supplies.
Discussions are ongoing, a European Commission spokesman told reporters Thursday. Remdesivir is one of only two medicines with a proven effect against the coronavirus, and the EU expects to clear it as a Covid-19 treatment by the end of this week.